Valvular heart disease associated with fenfluramine-phentermine
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Fenfluramine and phentermine have been individually approved as anorectic agents by the Food and Drug Administration (FDA). When used in combination the drugs may be just as effective as either drug alone, with the added advantages of the need for lower doses of each agent and perhaps fewer side effects. Although the combination has not been approved by the FDA, in 1996 the total number of prescriptions in the United States for fenfluramine and phentermine exceeded 18 million. METHODS: We identified valvular heart disease in 24 women treated with fenfluramine-phentermine who had no history of cardiac disease. The women presented with cardiovascular symptoms or a heart murmur. As increasing numbers of these patients with similar clinical features were identified, there appeared to be an association between these features and fenfluramine-phentermine therapy. RESULTS: Twenty-four women (mean [+/-SD] age, 44+/-8 years) were evaluated 12.3+/-7.1 months after the initiation of fenfluramine-phentermine therapy. Echocardiography demonstrated unusual valvular morphology and regurgitation in all patients. Both right-sided and left-sided heart valves were involved. Eight women also had newly documented pulmonary hypertension. To date, cardiac surgical intervention has been required in five patients. The heart valves had a glistening white appearance. Histopathological findings included plaque-like encasement of the leaflets and chordal structures with intact valve architecture. The histopathological features were identical to those seen in carcinoid or ergotamine-induced valve disease. CONCLUSIONS: These cases arouse concern that fenfluramine-phentermine therapy may be associated with valvular heart disease. Candidates for fenfluramine-phentermine therapy should be informed about serious potential adverse effects, including pulmonary hypertension and valvular heart disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Early weight loss medications, such as fenfluramine (Fen-Phen) and sibutramine, were withdrawn due to severe cardiovascular and psychiatric side effects [3,4].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“While effective (average 10–15% weight loss), fenfluramine was withdrawn in 1997 after studies linked it to valvular heart disease and pulmonary hypertension [3].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“While effective (average 10–15% weight loss), fenfluramine was withdrawn in 1997 after studies linked it to valvular heart disease and pulmonary hypertension [3].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“Certainly, starvation, very-low-calorie diets, liquid protein diets, and obesity surgeries have been associated with prolongation of the QTc interval and increased risk of malignant dysrhythmias (1), and various pharmacologic agents have either limited efficacy or considerable toxicity (70 -72).”
From Obesity and Cardiovascular Disease (2009) · cites this paper as [70]
Citations
Cites
Appetite-suppressant drugs and the risk of primary pulmonary hypertension
Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350901 · Cited by 1,162
Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.
Pellikka, P. A., Tajik, A. J., Khandheria, B. K., Seward, J. B., Callahan, J. A., Pitot, H. C., & Kvols, L. K. (1993) · Circulation · doi:10.1161/01.cir.87.4.1188 · Cited by 614
Robiolio, P. A., Rigolin, V. H., Wilson, J. S., Harrison, J. K., Sanders, L. L., Bashore, T. M., & Feldman, J. M. (1995) · Circulation · doi:10.1161/01.cir.92.4.790 · Cited by 406
Doppler Echocardiography: Theory, Instrumentation, Technique, and Application
NISHIMURA, R. A., MILLER, F. A., CALLAHAN, M. J., BENASSI, R. C., SEWARD, J. B., & TAJIK, A. J. (1985) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60540-0 · Cited by 263
Primary pulmonary hypertension and fenfluramine use.
Brenot, F., Herve, P., Petitpretz, P., Parent, F., Duroux, P., & Simonneau, G. (1993) · Heart · doi:10.1136/hrt.70.6.537 · Cited by 251
Weir, E. K., Reeve, H. L., Huang, J. M. C., Michelakis, E., Nelson, D. P., Hampl, V., & Archer, S. L. (1996) · Circulation · doi:10.1161/01.cir.94.9.2216 · Cited by 218
Klein, A. L., Burstow, D. J., Tajik, A. J., Zachariah, P. K., Taliercio, C. P., Taylor, C. L., Bailey, K. R., & Seward, J. B. (1990) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(14)80299-x · Cited by 213
Valve Disease Associated with Ergot Alkaloid Use: Echocardiographic and Pathologic Correlations
Redfield, M. M., Nicholson, W. J., Edwards, W. D., & Tajik, A. J. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-50 · Cited by 156
Self-citationHormonal responses to fenfluramine in depressed and control subjects
Mitchell, P. B., & Smythe, G. A. (1990) · Journal of Affective Disorders · doi:10.1016/0165-0327(90)90008-v · Cited by 99
Irreversible pulmonary hypertension after treatment with fenfluramine.
McMurray, J. J. V., Bloomfield, P. M., & Miller, H. (1986) · BMJ · doi:10.1136/bmj.292.6515.239-a · Cited by 50
Research works printed but not linked: 4
- Heuer L, 1978, Chir Prax, 23, 497
- Tajik AJ, 1978, Mayo Clin Proc, 53, 271
- Thorson AH, 1958, Acta Med Scand Suppl, 334, 99
- Morita T, 1983, Am Rev Respir Dis, 127, 747
Cited by
Items 701–800 of 1,001
Drolet, B., Simard, C., & Poirier, P. (2007) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200707040-00005 · Cited by 23
Rapid synthesis and lipase inhibition activity of some new benzimidazole and perimidine derivatives
Menteşe, E., Yılmaz, F., Karaali, N., Ülker, S., & Kahveci, B. (2014) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162014030091 · Cited by 25
Neuropeptide receptors as potential pharmacological targets for obesity
Meneguetti, B. T., Cardoso, M. H. E. S., Ribeiro, C. F. A., Felício, M. R., Pinto, I. B., Santos, N. C., Carvalho, C. M. E., & Franco, O. L. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.002 · Cited by 26
Herbal approach for obesity management
Preeti, S. (2018) · New Insights in Obesity Genetics and Beyond · doi:10.29328/journal.niogb.1001008 · Cited by 23
Effect of (−)-trans-PAT, a novel 5-HT2C receptor agonist, on intake of palatable food in mice
Rowland, N. E., Crump, E. M., NGUYEN, N., ROBERTSON, K., Sun, Z., & BOOTH, R. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.07.004 · Cited by 24
Wang, H., Wu, Y., Zhao, Y., Sun, W., Ding, L., Guo, B., & Chen, B. (2012) · Food Additives & Contaminants Part A · doi:10.1080/19440049.2012.692395 · Cited by 23
Adverse effects of benfluorex on heart valves and pulmonary circulation
Szymanski, C., Andréjak, M., Peltier, M., Maréchaux, S., & Tribouilloy, C. M. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3642 · Cited by 25
BORER, J. S., Pouleur, H. G., Abadie, E., Follath, F., Wittes, J. T., Pfeffer, M. A., Pitt, B., & Zannad, F. M. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm209 · Cited by 23
Spillover effects of prescription drug withdrawals
Cawley, J., & Rizzo, J. A. (2008) · Advances in health economics and health services research · doi:10.1016/s0731-2199(08)19006-9 · Cited by 23
“For example, in 1997 the Food and Drug Administration requested that Wyeth remove from the market its antiobesity drugs Pondimin and Redux that had been used by six million Americans because the drugs caused potentially fatal valvular heart disease (Connolly et al., 1997; Agovino, 2004).”
BackgroundKushner, R. F. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.8.1339 · Cited by 24
Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs
Burger, A. J., Charlamb, M. J., Singh, S., Notarianni, M., Blackburn, G. L., & Sherman, H. B. (2001) · International Journal of Cardiology · doi:10.1016/s0167-5273(01)00412-0 · Cited by 23
Hensrud, D. D. (2000) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70231-5 · Cited by 26
Self-citationA close look at fenfluramine and dexfenfluramine
Vivero, L. E., Anderson, P. O., & Clark, R. F. (1998) · Journal of Emergency Medicine · doi:10.1016/s0736-4679(97)00289-8 · Cited by 23
Kimmel, S. E., Keane, M. G., Crary, J. L., Jones, J. H., Kinman, J. L., Beare, J., Sammel, M. D., Sutton, M. S. J., & Strom, B. L. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00281-7 · Cited by 23
Self-citationEffects of sibutramine-induced weight loss on cardiovascular system in obese subjects
SIMONE, G. D., Romano, C., Caprio, C. D., Contaldo, F., Salanitri, T., Paparatti, U. D. L., & Pasanisi, F. (2005) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2004.07.002 · Cited by 25
“The interest for this new drug is also increased by the recent withdrawal from the market of dexfenfluramine, an appetite suppressant drug acting as an intracellular release inducer of 5-HT, because of description of serious adverse effect on cardiac valves [9,10].”
BackgroundTomita, T., & Zhao, Q. (2002) · CHEST Journal · doi:10.1378/chest.121.2.649 · Cited by 23
Measurement of human brain dexfenfluramine concentration by 19F magnetic resonance spectroscopy
Christensen, J. D., Yurgelun-Todd, D. A., Babb, S. M., Gruber, S. A., Cohen, B. M., & Renshaw, P. F. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01441-9 · Cited by 23
A critical evaluation of fenfluramine hydrochloride for the treatment of Dravet syndrome
Schoonjans, A., & Ceulemans, B. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1877540 · Cited by 22
A review of fenfluramine for the treatment of Dravet syndrome patients
Simon, K., Sheckley, H., Anderson, C. L., Liu, Z., & Carney, P. R. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100078 · Cited by 22
Heckmann, N. D., Palmer, R. C., Mayfield, C. K., Gucev, G., Lieberman, J. R., & Hong, K. M. (2024) · Arthroplasty Today · doi:10.1016/j.artd.2024.101327 · Cited by 23
Heart valve cardiomyocytes of mouse embryos express the serotonin transporter SERT
Pavone, L. M., Spina, A., Muto, R. L., Santoro, D., Mastellone, V., & Avallone, L. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.09.152 · Cited by 22
Bray, G. A. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20207 · Cited by 27
Cardiovascular Manifestations of Endocrine Dysfunction
Deegan, R., & Furman, W. R. (2011) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2010.12.001 · Cited by 23
Current Perspectives on Long-term Obesity Pharmacotherapy
Wharton, S. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.07.005 · Cited by 30
The Burden of Valvular Heart Disease
Mensah, G. A. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5892-2.00001-5 · Cited by 25
Recent Developments in Molecular Brain Imaging of Neuropsychiatric Disorders
Slifstein, M., & Abi‐Dargham, A. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.002 · Cited by 25
Pharmacotherapy for obesity in individuals with type 2 diabetes
Chukir, T., Shukla, A. P., Saunders, K. H., & Aronne, L. J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1428558 · Cited by 22
Joish, V. N., Shah, S. A., Tierce, J. C., Patel, D. M., McKee, C. M., Lapuerta, P., & Zacks, J. S. (2019) · Future Oncology · doi:10.2217/fon-2018-0960 · Cited by 22
New Horizons: Is Obesity a Disorder of Neurotransmission?
Caron, A., & Michael, N. J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab421 · Cited by 26
Reuptake Inhibitors of Dopamine, Noradrenaline, and Serotonin
Kintscher, U. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-24716-3_15 · Cited by 23
“While this study showed promising effects of fen–phen on long-term weight loss, routine clinical usage of the drug revealed rare but serious side effects mediated by the treatment, in particular cardiac valvulopathy and pulmonary hypertension (Connolly et al. 1997; Fishman 1999).”
BackgroundWechsler, J. G., & Leopold, K. (2003) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-003-0377-3 · Cited by 24
“The centrally acting agents fenfluramine and dexfenfluramine had to be withdrawn from the market in September 1997 due to the occurrence of unacceptable side effects such as valvular lesions with subsequent insufficiency of valves [1, 8].”
BackgroundAutomated support for pharmacovigilance: a proposed system
Bright, R. A., & Nelson, R. C. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.684 · Cited by 22
Drug Discrimination in Methamphetamine-Trained Monkeys: Effects of Monoamine Transporter Inhibitors
Czoty, P. W., Ramanathan, C. R., Mutschler, N. H., Makriyannis, A., & Bergman, J. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.071035 · Cited by 22
SEVERE HEPATOTOXICITY ASSOCIATED WITH CHINESE DIET PRODUCT ‘ONSHIDOU‐GENBI‐KOUNOU’
Kanda, T., Yokosuka, O., Okada, O., Suzuki, Y., & Saisho, H. (2003) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2003.02952.x · Cited by 22
Orexins and appetite: The big picture of energy homeostasis gets a little bigger
Schwartz, M. W. (1998) · Nature Medicine · doi:10.1038/nm0498-385 · Cited by 22
To whom do the research findings apply?
Furberg, C. D. (2002) · Heart · doi:10.1136/heart.87.6.570 · Cited by 22
Importance of Orexigenic Counter‐Regulation for Multiple Targeted Feeding Inhibition
SCHUSDZIARRA, V., Zimmermann, J., & Schick, R. (2004) · Obesity Research · doi:10.1038/oby.2004.72 · Cited by 24
Schoonjans, A., Roosens, L., Dewals, W., Paelinck, B. P., & Ceulemans, B. (2022) · Epilepsia · doi:10.1111/epi.17162 · Cited by 23
Lersch, R., Jannadi, R., Grosse, L., Wagner, M., Schneider, M. F., von Stülpnagel, C., Heinen, F., Potschka, H., & Borggraefe, I. (2022) · The Neuroscientist · doi:10.1177/10738584221088244 · Cited by 21
Castillero, E., Fitzpatrick, E., Keeney, S. J., D’Angelo, A. M., Pressly, B. B., Simpson, M. T., Kurade, M., Erwin, W. C., Moreno, V., Camillo, C., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adc9606 · Cited by 21
Reid, T.-E. R., Kumar, K., & Wang, X. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113139990039 · Cited by 23
Reducing the Risk of Obesity: Defining the Role of Weight Loss Drugs
Ling, H., Lenz, T. L., Burns, T. L., & Hilleman, D. E. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1277 · Cited by 23
Barbadin Potentiates Long-Term Effects of Lorcaserin on POMC Neurons and Weight Loss
He, Y., Liu, H., Yin, N., Yang, Y., Wang, C., Yu, M., Liu, H., Chen, L., Wang, J., Tu, L., et al. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.3210-20.2021 · Cited by 23
The patient with a heart murmur
Lessard, E., Glick, M., Ahmed, S., & Sarić, M. (2005) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2005.0176 · Cited by 21
Willison, D. J., & Sm, M. (1999) · Journal of Evaluation in Clinical Practice · doi:10.1046/j.1365-2753.1999.00193.x · Cited by 21
Determination of the Optical Purity of N-nitrosofenfluramine Found in the Chinese Slimming Diet
Nakadai, A., Inagaki, H., Minami, M., Takahashi, H., Namme, R., Ohsawa, M., & Ikegami, S. (2003) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.123.805 · Cited by 21
Effect of sibutramine on macronutrient selection in male and female rats
LeBlanc, M., & Thibault, L. (2003) · Physiology & Behavior · doi:10.1016/j.physbeh.2003.07.010 · Cited by 21
Rothman, R. B., Partilla, J. S., Dersch, C. M., Carroll, F. I., Rice, K. C., & Baumann, M. H. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05185.x · Cited by 21
Khajuria, V., Arora, E., Tandon, V., Sharma, A., Mahajan, A., Gillani, Z., & Choudhary, N. (2015) · Perspectives in Clinical Research · doi:10.4103/2229-3485.148812 · Cited by 21
THE TREATMENT OF OBESITY IN TYPE 2 DIABETES MELLITUS
Gumbiner, B. (1999) · Primary Care Clinics in Office Practice · doi:10.1016/s0095-4543(05)70136-6 · Cited by 24
Hirsch, J., & Leibel, R. L. (1998) · Hospital Practice · doi:10.1080/21548331.1998.11443653 · Cited by 26
Inhibition of Delayed Rectifier K+ Channels by Dexfenfluramine (Redux)
Hu, S., Wang, S., Gibson, J. C., & Gilbertson, T. A. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37817-6 · Cited by 22
Editorial: Uses and misuses of the new pharmacotherapy of obesity
Bray, G. A. (1999) · Annals of Medicine · doi:10.3109/07853899909019257 · Cited by 21
Prepublication Release ofJournalArticles
Kassirer, J. P., & Angell, M. E. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712113372409 · Cited by 21
Cardiovascular effects and safety of classic psychedelics
Nahlawi, A., Ptaszek, L. M., & Ruskin, J. N. (2025) · Nature Cardiovascular Research · doi:10.1038/s44161-025-00608-2 · Cited by 25
O’Gara, T., O’Rourke, R. A., Otto, C. M., Shah, P. M., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., Bonow, R. O., Carabello, B. A., et al. (2013) · Cited by 20
Effects of Cyproheptadine on Mitral Valve Remodeling and Regurgitation After Myocardial Infarction
Marsit, O., Clavel, M.-A. A., Paquin, A., Deschênes, V., Hadjadj, S., Senechal, I., Couët, J., Arsenault, M., Handschumacher, M. D., Levine, R. A., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.05.025 · Cited by 21
Heart failure and diabetes: Clinical significance and epidemiology of this two‐way association
Jerkins, T. W., McGill, J. B., & Bell, D. S. H. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15062 · Cited by 22
Nongonierma, A. B., Schellekens, H., Dinan, T. G., Cryan, J. F., & Fitzgerald, R. J. (2013) · Food & Function · doi:10.1039/c3fo30309h · Cited by 21
Phentermine: A Systematic Review for Plastic and Reconstructive Surgeons
Lim, S., Rogers, L. K., Tessler, O., Mundinger, G. S., Rogers, C. L., & Lau, F. H. (2018) · Annals of Plastic Surgery · doi:10.1097/sap.0000000000001478 · Cited by 20
Carcinoid Heart Disease: a Review
Laskaratos, F., Davar, J., & Toumpanakis, C. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01031-z · Cited by 20
Serotonin Transporters, Serotonin Release, and the Mechanism of Fenfluramine Neurotoxicity
Baumann, M. H., AYESTAS, M. A., Dersch, C. M., Partilla, J. S., & Rothman, R. B. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05194.x · Cited by 20
Overview and the Future of Obesity Treatment
Terre, L., Poston, W. S. C., & Foreyt, J. P. (2005) · Humana Press eBooks · doi:10.1385/1-59259-865-x:161 · Cited by 21
A comparison of d,l-fenfluramine and citalopram challenges in healthy adults
Flory, J. D., Manuck, S. B., Perel, J. M., & Muldoon, M. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1763-9 · Cited by 20
“In 1997, case reports were published that described valvular heart disease in women treated for weight loss with fenfluramine+phenteramine ( Connolly et al. 1997 ).”
BackgroundComputed Tomography and Magnetic Resonance Imaging of Patients With Valvular Heart Disease
Rozenshtein, A., & Boxt, L. M. (2000) · Journal of Thoracic Imaging · doi:10.1097/00005382-200010000-00005 · Cited by 21
Association of valvular heart disease with Chinese-herb nephropathy
Vanherweghem, J. (1997) · The Lancet · doi:10.1016/s0140-6736(05)63683-5 · Cited by 20
Vroonen, L., Lancellotti, P., Garcia, M. T., Dulgheru, R., Rubio-Almanza, M., Maiga, I., Magné, J., Pétrossians, P., Auriemma, R. S., Daly, A., et al. (2016) · Endocrine · doi:10.1007/s12020-016-1177-1 · Cited by 20
Aronne, L. J. (1998) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70599-x · Cited by 28
Alsuhibani, A., Alrasheed, M., Gari, M., Hincapie, A. L., & Guo, J. J. (2022) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-021-01330-2 · Cited by 19
Valvular heart disease in a patient taking 3,4‐methylenedioxymethamphetamine (MDMA, ‘Ecstasy’)
Montastruc, F., Montastruc, G., Vigreux, P., Bruneval, P., Guilbeau‐Frugier, C., Cron, C., Bagheri, H., Delisle, M. B., Lapeyre‐Mestre, M., Pathak, A., et al. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04252.x · Cited by 19
Stereoselectivity in Drug Action and Disposition: An Overview
Patel, B. K., & Hutt, A. J. (2004) · CRC Press eBooks · doi:10.1201/9780203021811-12 · Cited by 24
Drug-associated valvular heart diseases and serotonin-related pathways: a meta-analysis
Fortier, J. H., Pizzarotti, B., Shaw, R. E., Levy, R. J., Ferrari, G. M., & Grau, J. B. (2019) · Heart · doi:10.1136/heartjnl-2018-314403 · Cited by 20
3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands
Porter, M. R., Xiao, H., Wang, J., Smith, S. B., & Topczewski, J. J. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00225 · Cited by 20
Polyfluorinated scaffolds in drug discovery
Pertusati, F., Serpi, M., & Pileggi, E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812733-9.00003-9 · Cited by 20
Stiripentol for the treatment of seizures in Dravet syndrome
Eschbach, K. L., & Knupp, K. G. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1605904 · Cited by 19
Dave, G. S., Rakholiya, K., Kaneria, M., Galvadiya, B. P., Vyas, S. R., Kanbi, V. H., & Patel, M. P. (2020) · Phytotherapy Research · doi:10.1002/ptr.6796 · Cited by 19
“In contrast, Phentermine is associated with valvular heart disease—upon chronic exposure (Connolly et al., 1997).”
BackgroundNakagawa, Y., Suzuki, T., KAMIMURA, H., & Nagai, F. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.10.042 · Cited by 20
Clinical trial issues in weight-loss therapy
Patel, M. R., Donahue, M., Wilson, P. W. F., & Califf, R. M. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.03.006 · Cited by 19
Baptista, T., Lacruz, A., Acosta, A., Colasante, C., Quijada, M. D., Mendoza, S., Mendoza, J., & Hernández, L. (2000) · Appetite · doi:10.1006/appe.1999.0284 · Cited by 22
Orlistat in the treatment of obesity
Hollander, P. A. (2003) · Primary Care Clinics in Office Practice · doi:10.1016/s0095-4543(03)00042-3 · Cited by 20
Hillebrand, J. J., Heinsbroek, A. C. M., Kas, M. J., & Adan, R. A. H. (2005) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01887 · Cited by 19
Pharmacological and surgical treatments for obesity
DeWald, T. A., Khaodhiar, L., Donahue, M., & Blackburn, G. L. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.03.007 · Cited by 25
EFFECTS OF DIETARY MODIFICATION AND TREATMENT OF OBESITY
Stone, N. J., & Kushner, R. F. (2000) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70209-1 · Cited by 19
Carcinoid Heart Disease: an Update
Quaedvlieg, P., Lamers, C. B. H. W., & Taal, B. G. (2002) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655202320621481 · Cited by 19
Trans�sophageale Echokardiographie
Goetz, A. E., Eltzschig, H. K., Schroeder, T. H., Ehlers, R., & Felbinger, T. W. (2002) · Der Anaesthesist · doi:10.1007/s00101-001-0274-5 · Cited by 19
Akamatsu, S., & Mitsuhashi, T. (2013) · Drug Testing and Analysis · doi:10.1002/dta.1524 · Cited by 18
Switching and combining of dopamine agonists
Junghanns, S., Gl�ckler, T., & Reichmann, H. (2004) · Journal of Neurology · doi:10.1007/s00415-004-1605-7 · Cited by 18
“Fibrotic degeneration has also been described in patients on ergot-derived anorectic drugs and anti-migraine ergot alkaloid agents [ 4 , 7]. In these reports there are hints towards a potential dose-dependency of this complication.”
BackgroundTherapeutic Role of Phytomedicines on Obesity: Importance of Herbal Pancreatic lipase Inhibitors
Singh, S., & Kanwar, S. S. (2013) · Cited by 23
Drugs to treat obesity: do they work?
Kim, S. (2016) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2015-133388 · Cited by 20
Binge eating in pre-clinical models
Rospond, B., Szpigiel, J., Sadakierska−Chudy, A., & Filip, M. (2014) · Pharmacological Reports · doi:10.1016/j.pharep.2014.11.012 · Cited by 19
“Those life-threatening side effects of fenphen contributed to its withdrawal from the market by FDA in 1997 [26].”
BackgroundNext Generation of Weight Management Medications: Implications for Diabetes and CVD Risk
Wharton, S., & Serodio, K. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0590-z · Cited by 19
Bray, G. A., & Ryan, D. H. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.08.013 · Cited by 21
Pharmacological Treatment of Obesity
Yoo, S. J. (2008) · Journal of Korean Endocrine Society · doi:10.3803/jkes.2008.23.4.223 · Cited by 18
Lewellyn, K., Białońska, D., Loria, M. J., White, S. W., Sufka, K. J., & Zjawiony, J. K. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.09.011 · Cited by 19
Progressos recentes e novas perspectivas em farmacoterapia da obesidade
Faria, A. M., Mancini, M. C., de Melo, M. E., Cercato, C., & Halpern, A. (2010) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302010000600003 · Cited by 30
The application of prescribing indicators to a primary care prescription database in Ireland
Williams, D. J., Bennett, K., & Feely, J. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0876-3 · Cited by 18
Pergolide-Associated Valvular Heart Disease
Waller, E. A., & Kaplan, J. (2006) · Comprehensive Therapy · doi:10.1385/comp:32:2:94 · Cited by 19
“Drug-induced, or drug-associated, valvular heart disease (VHD) was brought to the forefront of both the medical community and the lay press in 1997 by Connolly et al. ( 1 ).”
BackgroundThe Fenfluramine Metabolite (+)-Norfenfluramine Is Vasoactive
Ni, W., Li, M. W., Thakali, K. M., Fink, G. D., & Watts, S. W. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.060806 · Cited by 18
“, 1996) and aortic valvular disease (Connolly et al., 1997).”
BackgroundInfluentialObesity Medications and the Treatment of Type 2 Diabetes
Greenway, F. (1999) · Diabetes Technology & Therapeutics · doi:10.1089/152091599317198 · Cited by 19
Epidemics of vascular toxicity and pulmonary hypertension: what can be learned?
Egermayer, P. (2000) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2000.00586.x · Cited by 18
Metadata
- Authors
- Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V.
- Affiliations
- Mayo Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1997-08-28
- Volume
- 337
- Issue
- 9
- Pages
- 581-588
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2134362869
- Cited by
- 1,632
- References
- 14
- Citations by year
- 2026: 23 · 2025: 23 · 2024: 26 · 2023: 43 · 2022: 32 · 2021: 40 · 2020: 35 · 2019: 39 · 2018: 42 · 2017: 55 · 2016: 54 · 2015: 58 · 2014: 51 · 2013: 55 · 2012: 59
- FWCI
- 72.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Issues in Pregnancy
- Keywords
- valvular heart disease, pulmonary hypertension, anorectic agents, women, adverse drug reactions
- MeSH terms
- Adult, Aortic Valve Insufficiency, Appetite Depressants, Drug Combinations, Female, Fenfluramine, Heart Valve Diseases, Humans, Hypertension, Pulmonary, Middle Aged, Mitral Valve, Mitral Valve Insufficiency, Phentermine, Tricuspid Valve Insufficiency, Ultrasonography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.